⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6445897 | 0.76 | — | — | |
| SCHEMBL15637781 | 0.75 | — | — | |
| SCHEMBL2128339 | 0.72 | — | — | |
| SCHEMBL3936677 | 0.72 | — | — | |
| SCHEMBL269536 | 0.71 | — | — | |
| SCHEMBL14659001 | 0.71 | — | — | |
| SCHEMBL2190608 | 0.69 | — | — | |
| SCHEMBL14052659 | 0.69 | — | — | |
| SCHEMBL287804 | 0.69 | — | — | |
| SCHEMBL9332469 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240229043-A1 | Methods and Compositions for Treating, Ameliorating, and/or Preventing Chronic Kidney Disease (CKD) and Complications thereof by Regulating DPEP1, CASP9, ACSS2 and/or FASN | UNIV PENNSYLVANIA (US) | 2024-07-11 | — | — | US | disclosed |
| US-11795136-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ACUCELA INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11759186-B2 | Ductus side-entry and prosthetic disorder response systems | Goldsmith, David S. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230100006-A1 | Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor and Pharmaceutical Use Therefor | THE KITASATO INSTITUTE (JP) | 2023-03-30 | — | — | US | disclosed |
| US-11377664-B2 | Formulations and methods for control of weedy species | TERRAMERA, INC. (CA) | 2022-07-05 | — | — | US | disclosed |
| US-20210171435-A1 | Methods for the Treatment of Diabetic Retinopathy and other Ophthalmic Diseases | ACUCELA INC. | 2021-06-10 | — | — | US | disclosed |
| EP-3741742-A1 | METHODS FOR THE TREATMENT OF DIABETIC RETINOPATHY AND OTHER OPHTHALMIC DISEASES | Acucela Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10730825-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ACUCELA INC. (US) | 2020-08-04 | — | — | US | disclosed |
| EP-2844636-B1 | METHODS FOR THE TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY | ACUCELA INC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-20180346407-A1 | Methods for the Treatment of Diabetic Retinopathy and other Ophthalmic Diseases | ACUCELA INC. | 2018-12-06 | — | — | US | disclosed |
| WO-2000069412-A1 | METHOD OF TREATING ANGINA AND/OR ANGINAL EQUIVALENTS, AND PHARMACEUTICAL COMPOSITIONS AND KIT RELATED THERETO | ESPERION LUV DEVELOPMENT, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| US-6080422-A | Methods of angioplasty and cardiac catheterization | TALARIA THERAPEUTICS, INC. (US) | 2000-06-27 | — | — | US | disclosed |
| EP-0863748-A4 | LIPOSOMAL COMPOSITIONS AND METHODS OF USING THEM | WILLIAM KEVIN JON (US) | 1999-11-03 | — | — | EP | disclosed |
| US-5948435-A | Methods of regulating CETP genes, enzymes and other compound, and pharmaceutical composition therefor | TALARIA THERAPEUTICS, INC. (US) | 1999-09-07 | — | — | US | disclosed |
| US-5858400-A | Method of suppressing a rise in LDL concentrations after administration of an agent having small acceptors | TALARIA THERAPEUTICS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5843474-A | Method of dialysis treatment, and dialysis apparatus related thereto | REVERSE TRANSPORT LICENSING & CONSULTING, INC. (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0863748-A1 | LIPOSOMAL COMPOSITIONS AND METHODS OF USING THEM | William, Kevin Jon (US) | 1998-09-16 | — | — | EP | disclosed |
| US-5746223-A | Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis | PFIZER INC. | 1998-05-05 | — | — | US | disclosed |
| US-5736157-A | Method of regulating cholesterol related genes, enzymes and other compounds, and pharmaceutical compositions | PFIZER INC. | 1998-04-07 | — | — | US | disclosed |
| WO-1997013501-A1 | LIPOSOMAL COMPOSITIONS AND METHODS OF USING THEM | WILLIAMS KEVIN JON (US) | 1997-04-17 | — | — | WO | disclosed |